Anas Alshawa

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Phase 2 study of pembrolizumab in patients with advanced rare cancers”.

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000347

N/A

4.0DataRank · unranked

131 citations

Funda Meric‐Bernstam, Bettzy Stephen, Daniel D. Karp, Joud Hajjar, Jordi Rodon Ahnert +35 more

Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-000665

N/A

0.821DataRank · unranked

12 citations

Phyu P. Aung, Sinchita Roy‐Chowdhuri, Mingxuan Xu, Fengying Ouyang, Anas Alshawa +11 more

Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies

Cancer(2023)10.1002/cncr.35063

N/A

0DataRank · unranked

17 citations

Jibran Ahmed, Bettzy Stephen, Sarina A. Piha‐Paul, Daniel D. Karp, Abdulrazzak Zarifa +13 more

584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0584

N/A

0DataRank · unranked

0 citations

Anne Knisely, Bettzy Stephen, Yali Yang, Juhee Song, Anas Alshawa +9 more